혈장 유래 단백질 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Plasma-Derived Protein Therapies Market size is expected to reach USD 70.16 Billion in 2034 from USD 39.27 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The global plasma-derived protein therapies market is witnessing significant growth due to the increasing prevalence of rare and chronic diseases that require specialized treatment. Plasma-derived protein therapies are used to treat a variety of medical conditions, including immune deficiencies, bleeding disorders, and neurological diseases. The growing demand for effective biologic treatments is driving the expansion of plasma collection and processing facilities worldwide.

Several factors are fueling the growth of this market, including advancements in plasma fractionation technologies and rising investments in biopharmaceutical research. Increased awareness about rare diseases and improved diagnostic capabilities are also contributing to higher treatment adoption rates. Additionally, the expansion of plasma donation centers is helping to ensure a stable supply of raw materials for the production of these therapies.

In the future, the plasma-derived protein therapies market is expected to expand further as new therapeutic applications continue to emerge. Ongoing research in immunology and neurology is likely to create new opportunities for plasma-based treatments. With increasing healthcare expenditure and expanding access to advanced therapies, the market is poised for sustained growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Albumin
• Immunoglobulin
• Plasma-derived Factor VIII
• Others

By Application

• Hemophilia
• Primary Immunodeficiency Disorder (PIDD)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

COMPANIES PROFILED

• Bio Products Laboratory Ltd, Octapharma AG, CSL Limited, Grifols, SA, Taibang Biological Group Co, Ltd, Takeda Pharmaceutical Company Limited, ADMA Biologics Inc, Bayer AG, Baxter International Inc, Kedrion, SpA, Biotest AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA-DERIVED PROTEIN THERAPIES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Plasma-derived Factor VIII Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA-DERIVED PROTEIN THERAPIES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Primary Immunodeficiency Disorder (PIDD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Idiopathic Thrombocytopenic Purpura (ITP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA-DERIVED PROTEIN THERAPIES MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PLASMA-DERIVED PROTEIN THERAPIES INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Bio Products Laboratory Ltd
  • 8.2.2 Octapharma AG
  • 8.2.3 CSL Limited
  • 8.2.4 Grifols, S.A
  • 8.2.5 Taibang Biological Group Co., Ltd
  • 8.2.6 Takeda Pharmaceutical Company Limited
  • 8.2.7 ADMA Biologics Inc
  • 8.2.8 Bayer AG
  • 8.2.9 Baxter International Inc
  • 8.2.10 Kedrion, SpA
  • 8.2.11 Biotest AG